Semnur Q2 2026: $39k Cash, Going Concern Warning, and a $100M Lifeline Term Sheet
SMNR has more than doubled off its 52-week low of $0.25 on light trading volume (0.2× avg).
Summary
Semnur's Q2 2026 10-Q reveals a near-empty treasury ($39k cash), a going concern warning, and a binding term sheet for a $100M investment at $10.00/share — a potential lifeline at a huge premium to the $0.75 stock price.
Key Events · Earnings and Guidance · SMNR
-
Cash Position Near Zero
Cash and cash equivalents fell to $39,000 as of June 30, 2026, down from $20,000 at year-end 2025. The company burned $4.8 million in operations during H1 2026.
-
Going Concern Warning Reiterated
Management again expresses substantial doubt about the company's ability to continue as a going concern, citing recurring losses, negative cash flows, and dependence on parent Scilex for funding.
-
$100M Investment Term Sheet Signed
On July 3, 2026, Semnur entered a binding term sheet with iHolding Group LLP for a $100 million equity investment at $10.00 per share — a more than 12x premium to the current $0.75 stock price. The deal is subject to due diligence and definitive agreements, with no fixed completion date.
-
Prior Financing Deals Terminated
In April 2026, Semnur terminated both the $20 million PIPE SPA and the $100 million Semnur/Biconomy SPA, eliminating $120 million in previously announced financing.
Analysis · SMNR · Life Sciences
With just $39,000 in cash at June 30, 2026, and operating losses of $8.8 million for the first half, Semnur is running on fumes. The auditor's going concern warning is repeated, and material weaknesses in internal controls remain unfixed. A potential lifeline emerged on July 3, when a binding term sheet was signed for a $100 million equity investment at $10.00 per share — a massive premium to the current $0.75 stock price. If that deal closes, it would be transformative, but the term sheet is non-binding on completion and subject to due diligence. Underscoring the desperation, the company also terminated two previously announced financing deals totaling $120 million in April. Adding to the overhang, Scilex distributed 13.97 million Semnur shares to its own holders in Q2.
At the time of this filing, SMNR was trading at $0.75 on OTC in the Life Sciences sector, with a market capitalization of approximately $172.7M. The 52-week trading range was $0.25 to $23.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.